article thumbnail

What’s the next step in big data and AI?

Drug Discovery World

Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? His work provides insight into AI and big data in relation to pharma and drug discovery– now and in the future. “AI Up front collection and controlling your data! His advice?

article thumbnail

How digital innovation is helping therapeutics to get to market faster

Drug Discovery World

Biopharma and biotech companies without these capabilities are keen to harness these technologies and the number of strategic partnerships with such companies is accelerating at an unprecedented rate.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EMA pilot will see if clinical trial data should be digested ‘raw’

pharmaphorum

A pilot study has been launched by the EMA to see whether it is helpful for regulators to look at the ‘raw data’ from clinical trials submitted in support of new marketing application along with the usual structured analyses from sponsors.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

article thumbnail

The new technologies strengthening pharmaceutical supply chains

Pharmaceutical Technology

According to a recent GlobalData report, healthcare professionals have – for the second year in a row – ranked artificial intelligence (AI) and Big Data as the top two technologies revolutionising the pharmaceutical sector. The legacy of this disruption has been a rethink in the way pharma companies do business.

Big Data 130
article thumbnail

A history of AstraZeneca

pharmaphorum

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. Opportunities Originator pharma companies are developing more and more complex products these days. This adds between 1.5